Privium Fund Management B.V. Purchases New Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)

Privium Fund Management B.V. acquired a new position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) in the 4th quarter, HoldingsChannel reports. The firm acquired 325,709 shares of the company’s stock, valued at approximately $4,537,000. Arcutis Biotherapeutics makes up approximately 1.0% of Privium Fund Management B.V.’s holdings, making the stock its 21st largest position.

A number of other hedge funds have also made changes to their positions in ARQT. Victory Capital Management Inc. raised its position in shares of Arcutis Biotherapeutics by 9.9% in the third quarter. Victory Capital Management Inc. now owns 12,843 shares of the company’s stock valued at $119,000 after buying an additional 1,155 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in Arcutis Biotherapeutics by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 24,818 shares of the company’s stock worth $346,000 after acquiring an additional 2,336 shares during the last quarter. Point72 DIFC Ltd purchased a new stake in Arcutis Biotherapeutics during the 3rd quarter valued at about $25,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Arcutis Biotherapeutics by 1.1% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 276,691 shares of the company’s stock valued at $2,573,000 after acquiring an additional 2,912 shares during the last quarter. Finally, Venturi Wealth Management LLC purchased a new position in Arcutis Biotherapeutics in the 4th quarter worth approximately $46,000.

Arcutis Biotherapeutics Stock Performance

NASDAQ ARQT opened at $15.87 on Wednesday. The stock has a fifty day simple moving average of $13.55 and a 200-day simple moving average of $11.92. The company has a current ratio of 2.46, a quick ratio of 2.38 and a debt-to-equity ratio of 0.67. The stock has a market cap of $1.88 billion, a PE ratio of -8.87 and a beta of 1.48. Arcutis Biotherapeutics, Inc. has a twelve month low of $6.99 and a twelve month high of $17.70.

Arcutis Biotherapeutics (NASDAQ:ARQT) last posted its earnings results on Tuesday, February 25th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.19. Arcutis Biotherapeutics had a negative net margin of 140.97% and a negative return on equity of 119.11%. The company had revenue of $71.36 million for the quarter, compared to analysts’ expectations of $60.52 million. Equities analysts anticipate that Arcutis Biotherapeutics, Inc. will post -1.33 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently issued reports on ARQT. Needham & Company LLC restated a “buy” rating and issued a $20.00 price target on shares of Arcutis Biotherapeutics in a research report on Wednesday, February 26th. Guggenheim restated a “buy” rating on shares of Arcutis Biotherapeutics in a report on Monday, February 24th. Jefferies Financial Group lifted their price target on Arcutis Biotherapeutics from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Tuesday, March 11th. Mizuho upped their price objective on shares of Arcutis Biotherapeutics from $20.00 to $21.00 and gave the company an “outperform” rating in a report on Wednesday, February 26th. Finally, The Goldman Sachs Group lifted their target price on shares of Arcutis Biotherapeutics from $13.00 to $15.00 and gave the stock a “neutral” rating in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $18.80.

Insider Buying and Selling

In other Arcutis Biotherapeutics news, insider Patrick Burnett sold 12,242 shares of Arcutis Biotherapeutics stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $15.04, for a total value of $184,119.68. Following the completion of the transaction, the insider now directly owns 121,936 shares of the company’s stock, valued at $1,833,917.44. The trade was a 9.12 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Todd Franklin Watanabe sold 15,000 shares of the business’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $15.17, for a total transaction of $227,550.00. Following the sale, the insider now owns 823,430 shares in the company, valued at $12,491,433.10. This trade represents a 1.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 70,090 shares of company stock valued at $981,768. Company insiders own 9.50% of the company’s stock.

Arcutis Biotherapeutics Profile

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.